News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INNOPHARMA To Present At The 32nd Annual J.P. Morgan Healthcare Conference



1/6/2014 8:45:19 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

PISCATAWAY, N.J., Jan. 6, 2014 /PRNewswire/ -- InnoPharma, Inc., a privately held company focused on developing first to file and first to market opportunities in the complex generic and specialty pharmaceutical product space, is pleased to announce that it is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference at 8:00 am PT on January 15, 2014. The conference will be held at the Westin St. Francis Hotel in San Francisco.

Navneet Puri, Ph.D., President and Chief Executive Officer of InnoPharma, will provide a company overview during the presentation. A copy of the presentation will be available after the conclusion of the live event at www.innopharmainc.com.

About InnoPharma, Inc.
InnoPharma is a sterile product development company, focused on developing complex generic and innovative products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under development, with formulations including solutions, suspension, lyophilized, emulsions, liposomes, micelles and lipid complexes. InnoPharma's pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at www.innopharmainc.com.

SOURCE InnoPharma, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES